Biomedical subjects

R E Stauber

Publications and source records attributed to R E Stauber.

40 records · Page 3Linked to original sources

PubMed1990

Evidence for modulation of hepatic mass by estrogens and hepatic "feminization".

Animals with end-to-side portacaval shunts and sham-operated animals, wherein the body weight and liver weight of the animals varied spontaneously over a considerable range, were studied. The relationships between hepatic androgen- and estrogen-receptor content, serum testosterone and estradiol levels and hepatic mass were characterized. Animals with portacaval shunts were smaller than those without shunts. Moreover, they had reduced serum levels of testosterone and estradiol. The reduction in serum testosterone was greater than that of estradiol. As a result, the calculated estrogen/testosterone ratio of the two groups of animals was greater for the portacaval shunt animals than for the controls. The dissociation constant values for the androgen receptor and estrogen receptor in the liver did not differ between groups. The activity of the androgen receptor (p less than 0.01) and estrogen receptor (p less than 0.05) was reduced markedly in the animals with portacaval shunts compared with controls. Moreover, the hepatic cytosolic estrogen receptor activity--but not that of the androgen receptor--correlated with the measured hepatic mass in both groups of animals. These data suggest that hepatic feminization is either associated with or is a hepatic regenerative signal in the rat.

Animals↗

PubMed1990

Serum-ascites albumin gradients in nonalcoholic liver disease.

Several studies performed in alcoholics with advanced liver disease have demonstrated a positive correlation between the serum-ascites albumin gradient (SAAG) and measured portal venous pressure. A single study performed in 15 patients with exudative malignant ascites and 29 patients with alcoholic liver disease demonstrated that a SAAG of less than 1.1 was essentially diagnostic of a malignant origin of the ascites. In an effort to confirm and extend these observations to individuals with nonalcoholic liver disease, 24 patients with nonalcoholic liver disease and 11 with alcoholic liver disease undergoing orthotopic liver transplantation (OTLx) were studied. At the time of liver transplantation, each had their serum and ascitic fluid albumin levels determined, the gradient calculated, and their portal venous pressure (PVP) as well as the corrected portal venous pressure (PPc) measured directly. A significant correlation (r = 0.624) between the PPc and the SAAG was found in the 11 alcoholics (P less than 0.05). No such correlation existed for those with nonalcoholic liver disease (r = 0.398). Moreover, a SAAG less than 1.1 was found in three of nonalcoholics with cirrhosis in the absence of an abdominal malignancy. We conclude that (1) the SAAG and PPc are statistically related to each other in individuals with alcoholic liver disease but not in those with a nonalcoholic cause for cirrhosis, and (2) SAAG less than 1.1 is not diagnostic of abdominal malignancy but can occur in those with advanced nonmalignant hepatic disease.

Adult↗

PubMed1988

[Serum bile acids in diffuse liver parenchymal damage and their relation to ultrasound diagnosis].

40 patients with sonographically detected diffuse liver diseases of different severity and 8 controls with normal ultrasound of the liver were evaluated for fasting concentrations of serum bile acids (SBA) using an enzymatic method. Differences of SBA levels were significant among 4 groups classified as to severity by ultrasonography; SBA levels above 4.6 mumol/l were specific for the more severe grades of liver disease. Measurement of SBA and the evaluation of echographic patterns may be helpful in the decision to perform a liver biopsy.

Bile Acids and Salts↗

PubMedDate not supplied

Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.

OBJECTIVE: To define the usefulness of molecular parameters in patients with chronic hepatitis C who are undergoing antiviral therapy. Anti-hepatitis C virus (HCV) treatment was monitored by determination of serum HCV load and by presence of HCV RNA in peripheral blood mononuclear cells (PBMCs). STUDY DESIGN/METHODS: Fifty-one patients with chronic hepatitis C undergoing antiviral therapy with interferon-alpha plus ribavirin were studied. Serum HCV RNA load was tested with a quantitative assay (Amplicor HCV Monitor Test) before, during, and up to 12 months after end of treatment. If HCV RNA was not detectable, serum samples were subsequently tested with a qualitative assay (Cobas Amplicor HCV Test) and corresponding ethylenediaminetetraacetic acid (EDTA)-treated blood was checked for presence of HCV RNA in peripheral blood mononuclear cells (PBMCs). Sustained virologic response was defined by loss of HCV RNA 12 months after the end of treatment. RESULTS: Four patients (7.8%) were found to be sustained virologic responders, 17 (33.3%) were transient virologic responders, and 30 (58.8%) were virologic nonresponders. No significant difference was found in the median pretreatment serum HCV RNA load between sustained virologic responders, transient virologic responders, and virologic nonresponders. At 1 month after start of therapy, HCV RNA was not detectable with both the serum and the PBMC assay in 12 (23.5%) of 51 patients. Four remained HCV RNA-negative until 12 months after the end of treatment. In 14 of 17 transient virologic responders, reappearance of HCV RNA was detected earlier in PBMCs than in serum. CONCLUSIONS: Based on these results in 51 patients, quantitation of baseline serum HCV RNA does not appear to be a decisive factor to the management of the individual patient. Early assessment of serum HCV RNA level after start of anti-viral treatment seems to be of major importance to identify virologic nonresponders. Reappearance of HCV RNA may be demonstrated earlier in PBMCs than in serum.

Adult↗